Icatibant Al

Icatibant, the active ingredient in Icatibant Al, is a Bradykinin B2 receptor antagonist presented as a solution for injection for subcutaneous use. It treats acute attacks of hereditary angioedema type I and type II in patients with hereditary angioedema.

GNH USA supplies Icatibant Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Icatibant is a selective bradykinin B2 receptor antagonist used to manage hereditary angioedema attacks.

- Acute attacks of hereditary angioedema type I: provides rapid reduction of swelling and pain. - Acute attacks of hereditary angioedema type II: alleviates edema and improves airway patency. - Hereditary angioedema (any type): offers prompt symptom control during episodic flare‑ups.

Icatibant may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Injection site pain: discomfort at the subcutaneous injection site. - Redness or swelling at injection site: localized erythema. - Nausea: mild gastrointestinal upset. - Headache: transient cranial discomfort. - Dizziness: occasional light‑headedness. - Flushing: brief warmth or redness of the skin.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Angioedema unrelated to HAE: unexpected swelling in other body parts. - Hypotension: significant drop in blood pressure. - Severe injection‑site reactions: necrosis or ulceration. - Thrombocytopenia: low platelet count observed in rare cases.

Before using Icatibant, consider the following safety measures.

- Pregnancy: safety not established; use only if benefit outweighs potential risk. - Breastfeeding: unknown excretion; weigh maternal benefit against infant risk. - Renal impairment: no dosage adjustment required, but monitor for accumulation. - Concomitant ACE inhibitors or neprilysin inhibitors: may increase bradykinin levels; observe for enhanced edema. - Hypersensitivity: discontinue immediately if signs of allergic reaction appear. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other agents that influence the bradykinin pathway or cardiovascular function.

Major Interactions (Avoid): - ACE inhibitors: may potentiate bradykinin‑mediated effects, increasing risk of angioedema. - Neprilysin inhibitors (e.g., sacubitril): elevate bradykinin levels, heightening adverse‑event potential. - Other bradykinin‑potentiating drugs: additive risk of swelling.

Moderate Interactions (Monitor Closely): - Diuretics: may affect blood pressure when combined with hypotensive episodes. - Antihypertensive agents: monitor for excessive blood pressure reduction. - Other subcutaneous biologics: assess injection‑site tolerance when administered concurrently.